In a report released today, Chad Messer from Needham reiterated a Buy rating on CTI BioPharma (CTIC), with a price target of $6.00. The company’s shares closed last Monday at $3.38.
According to TipRanks.com, Messer is a 5-star analyst with an average return of 11.9% and a 50.2% success rate. Messer covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Aeglea Biotherapeutics, and Ionis Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for CTI BioPharma with a $6.25 average price target, which is a 79.6% upside from current levels. In a report issued on November 30, Brookline Capital Markets also assigned a Buy rating to the stock with a $7.00 price target.
See today’s analyst top recommended stocks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CTI BioPharma Corp. operates as a biopharmaceutical company, which focuses on the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. Its products include PIXUVRI, Pacritinib, Tosedostat and Opaxio. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.